Novavax's loss under GAAP for 9 months of 2020 was $240.695 million, up 2.4 times from $100.864 million the previous year. Revenue increased 20 times to $195.939 million, against $9.846 million a year earlier.
Novavax's loss under GAAP for 9 months of 2020 was $240.695 million, up 2.4 times from $100.864 million the previous year. Revenue increased 20 times to $195.939 million, against $9.846 million a year earlier. 
ir.novavax.com
English (US) 